TheEdgeResearch
Home / Stocks / UBIO

ProShares UltraPro Nasdaq Biotechnology (UBIO)

NASDAQ Financial Services Asset Management - Leveraged
$17.77 ▲ +0.00%
Market Cap
$15.1M
Sector
Financial Services
Industry
Asset Management - Leveraged
Beta
3.15
52-Wk Range
13.13-34.8
CEO
Country
Currency
USD

ProShares UltraPro Nasdaq Biotechnology operates in the Asset Management - Leveraged industry of the Financial Services sector. The stock last traded at $17.77, up 0.00% on the session, giving a market capitalisation of $15.1M. Its beta of 3.15 implies it has historically moved more than the broad market.

Company profile
Exchange
NASDAQ Global Market
Employees
IPO date
2015-06-22
Headquarters
About ProShares UltraPro Nasdaq Biotechnology

This fund aims to deliver daily returns equal to three times (3x) the daily movement of the NASDAQ Biotechnology Index, prior to accounting for fees and operating costs. To achieve this, it strategically deploys capital into various financial instruments, which ProShare Advisors expects will collectively mirror its ambitious daily performance target. The underlying index itself is a modified capitalization-weighted benchmark, comprising stocks of companies listed on Nasdaq that fall within the biotechnology or pharmaceutical sectors. It operates as a non-diversified fund.

Comparable companies

ProShares UltraPro Nasdaq Biotechnology is most often compared with the following Financial Services names:

BNKOCLDSDUDEFEULFLYTFONEGREIJHMFLBJRWVG
More research on UBIO
UBIO technical analysis UBIO TheEdge Score Compare against peers
Open full interactive analysis & DCF →